On January 16, 2026, guests attending the Enlarged Council Meeting of the Ningbo Intellectual Property Association visited Zhejiang Tianyuan Biotechnology Co., Ltd. (hereinafter referred to as "Tianyuan Biotech") for a tour and exchange. Ms. Zhu Youwu, Chief Administrative Officer of Tianhao Group (the President Unit of the Association), and Mr. Jiao Mingming, General Manager of Tianyuan Biotech (a subsidiary of the Group), led their teams in extending a warm welcome and cordial reception to the attendees.

      At the beginning of the event, member representatives toured the Science and Technology Exhibition Hall under the guidance of General Manager Jiao Mingming. The detailed presentation of achievements and vivid depictions of future prospects in the bio-health industry provided the representatives with an intuitive and in-depth understanding of the field. Attendees spoke highly of Tianyuan Biotech’s fruitful accomplishments in scientific research and innovation.

      Following the tour, the 6th Enlarged Council Meeting of the 5th Session of the Ningbo Intellectual Property Association was convened. Mr. Huang Bisheng, President of the Association and Chairman of Tianhao Group, delivered the annual work report. President Huang comprehensively reviewed the Association's achievements over the past year and outlined a forward-looking plan for future development. He emphasized that the Association would continue to leverage its platform role, integrate resources, provide superior services to member units, and foster innovative development across the industry.

      Subsequently, General Manager Jiao Mingming presented a detailed overview of Tianyuan Biotech’s business pipeline and development blueprint. He noted that the company has always adhered to technological innovation as its core driving force, committed to translating cutting-edge biotechnology into universally accessible health services. Looking ahead, Tianyuan Biotech will continue to deepen its expertise in core areas such as cell banking, cell preparation, medical testing, and health management. By leveraging its internationally leading iPSC-derived cardiomyocyte technology and utilizing research platforms including the National Health Commission (NHC) Research Institute, the National Stem Cell Translational Resource Bank, and the Institute of Biomedical Innovation at Ningbo University, the company aims to continuously expand its business boundaries and make greater contributions to human health.

      To enhance member units' scientific understanding of the biomedical field, two high-level popular science lectures were specially arranged. Mr. Yao Jincheng, Director of Tianyuan Biotech’s Testing Laboratory, delivered an engaging presentation titled "Managing Sub-health Status: Sustaining Vitality." Drawing on his extensive professional experience, he offered valuable health guidance to the guests. This was followed by a lecture by Dr. Liu Guangcheng, Director of the Cell Laboratory, titled "Exploring the Twins of Cell Therapy: From Scientific Principles to Medical Revolution." Through vivid language and detailed case studies, Dr. Liu guided the audience through the scientific mysteries of cell therapy.

      The successful hosting of this visit and exchange not only provided member units of the Ningbo Intellectual Property Association with a valuable opportunity to experience the charm of biomedical technology up close but also established an efficient platform for gaining deeper industry insights and exploring collaborative opportunities. Through this event, member units gained a clearer understanding of Tianyuan Biotech’s research capabilities and development vision, expressing strong anticipation for deepened cooperation in areas such as intellectual property protection, technology transfer, and market expansion.

      Founded in 2017, Zhejiang Tianyuan Biotechnology Co., Ltd. is a national high-tech enterprise dedicated to cell research and development, manufacturing, operations, and services. The company possesses valuable resource banks, including an HLA Umbilical Cord Matching Bank, an iPS Seed Cell Bank, and a Tumor Cell Bank. It is also a participating unit in formulating the group standard for immune function assessment methods under the National Health Commission (NHC). Furthermore, Tianyuan Biotech has co-established the Joint Laboratory for Metabolic Immune Monitoring with the NHC Research Institute, and serves as key research service platforms such as the Ningbo Storage Center of the National Stem Cell Translational Resource Bank and the Achievement Transformation Center of the NHC Research Institute.